Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

7.1%

4 terminated/withdrawn out of 56 trials

Success Rate

90.2%

+3.7% vs industry average

Late-Stage Pipeline

48%

27 trials in Phase 3/4

Results Transparency

16%

6 of 37 completed trials have results

Key Signals

8 recruiting6 with results

Enrollment Performance

Analytics

Phase 3

26(50.0%)

Phase 2

21(40.4%)

Phase 1

2(3.8%)

N/A

2(3.8%)

Phase 4

1(1.9%)

52Total

Phase 3(26)

Phase 2(21)

Phase 1(2)

N/A(2)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (56)

Showing 20 of 56 trials

NCT02466737Not ApplicableActive Not Recruiting

Comparison of Axillary Sentinel Lymph Node Biopsy Versus no Axillary Surgery

Role: collaborator

NCT05633654Phase 3Recruiting

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

Role: collaborator

NCT04595565Phase 3Active Not Recruiting

Sacituzumab Govitecan in Primary HER2-negative Breast Cancer

Role: lead

NCT07237256Phase 3Recruiting

Chemotherapy De-escalation in HR +, HER2-, Intermediate-risk Early Breast Cancer Treated With Adjuvant Ribociclib

Role: collaborator

NCT02947685Phase 3Active Not Recruiting

Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer

Role: collaborator

NCT06201234Phase 2Recruiting

Evaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer

Role: lead

NCT01772472Phase 3Completed

A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)

Role: collaborator

NCT04622319Phase 3Active Not Recruiting

A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)

Role: collaborator

NCT06607757Phase 2Recruiting

Capivasertib Plus Fulvestrant vs. Fulvestrant in Primary High-risk Lobular Breast Cancer

Role: lead

NCT04373655Recruiting

AXillary Surgery After NeoAdjuvant Treatment

Role: collaborator

NCT05306041Phase 2Recruiting

Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast Cancer

Role: lead

NCT00798070Phase 3Active Not Recruiting

Panther: A Study Comparing Biweekly and Tailored EC-T Versus Three Weekly FEC-T in Breast Cancer Patients

Role: collaborator

NCT05739591Recruiting

Long-term Safety and Efficacy of GBG Study Participants

Role: lead

NCT03355157Phase 4Completed

A Randomized, Open-label, Multi-center Phase IV Study Evaluating Palbociclib Plus Endocrine Treatment Versus a Chemotherapy-based Treatment Strategy in Patients With Hormone Receptor Positive / HER2 Negative Breast Cancer in a Real World Setting (GBG 93 - PADMA Study).

Role: lead

NCT00196833Recruiting

Breast Cancer in Pregnancy Register Study

Role: lead

NCT01864746Phase 3Completed

A Study of Palbociclib in Addition to Standard Endocrine Treatment in Hormone Receptor Positive Her2 Normal Patients With Residual Disease After Neoadjuvant Chemotherapy and Surgery

Role: lead

NCT03555877Phase 2Completed

Anti-hormonal Therapie With Ribociclib in HR-positive / HER2- Negative Metastatic Breast Cancer

Role: lead

NCT00545077Phase 3Completed

Bevacizumab + Endocrine Treatment vs Endocrine Treatment as First Line in Postmenopausal Women

Role: collaborator

NCT01498458Phase 1Completed

Pazopanib in Combination With Capecitabine in Patients With Metastatic Breast Cancer

Role: lead

NCT02387099Phase 2Completed

Dose EScalation Induction of EvERolimus

Role: lead